MedTrace Logo

Evaluation of the Potential for Cytochrome P450 3A4 Inhibition by F901318 Using Oral Midazolam as a Probe

NCT02680808 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2016-06-09

No results posted yet for this study

Summary

Open label evaluation of potential interaction of F901318 with cytochrome P450 3A4 using midazolam as a probe. Twenty healthy male subjects will participate

Conditions

  • Invasive Aspergillosis

Interventions

DRUG

Midazolam with F901318

Pharmacokinetics of midazolam with F901318

Sponsors & Collaborators

  • Hammersmith Medicines Research

    collaborator OTHER

  • F2G Biotech GmbH

    lead INDUSTRY

Principal Investigators

  • FRANS VANDENBERG · Hammersmith Medicines Research

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02680808 on ClinicalTrials.gov